IL6 and Autoimmunity: IL-5, IL-6, IL-13, IL-17, IL-23, and TNF-α are targetable with biologics developed for spontaneous autoimmunity, and our data broadly support the prospective investigation of these inhibitors for patients with irAEs (21–23, 26, 27, 62).